← Leaderboards
Ruihong Chen
Nexgenix Pharmaceuticals, Inc.
$277,482
Attributed
$437,482
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $177.7K · FY2009–11$200K$150K$100K$50K$0
'09
'10
'11
Funding mix
By agency
NIH$437,482 · 2
By mechanism
R21$320,000 · 1
R43$117,482 · 1
Top collaborators
- Heather Durham2 shared
Most similar at Nexgenix Pharmaceuticals, Inc.
Same institution · by research overlap
- Heather Durham$160,000
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsMolecular ChaperonesIn VitroPre-ClinicalSeriesClientHeat-Shock Proteins 90Inhibitor/AntagonistMolecular ConformationPenetrationDrug KineticsPublic Health RelevanceBrainBlood - Brain Barrier AnatomyBaseDoseHsp 90 InhibitionCellsIn VivoEmbryoEffectivenessEpigenetic ProcessAmyotrophic Lateral SclerosisDrug Development
Grant awards (3)
Novel Hsp90 Inhibitors: Proof-of-Principle for Treatment of Motor Neuron Diseases$142,280
R21 · FY2011 · NS · contact PI
Novel Hsp90 Inhibitors: Proof-of-Principle for Treatment of Motor Neuron Diseases$177,720
R21 · FY2010 · NS · contact PI
Novel Small Molecule Hsp90 Therapeutics to Treat Glioma$117,482
R43 · FY2009 · NS · contact PI